Tolterodine: a review of its use in the treatment of overactive bladder

Drugs & Aging
D Clemett, B Jarvis

Abstract

Tolterodine is a competitive muscarinic receptor antagonist that shows in vivo selectivity for the bladder over the salivary glands compared with oxybutinin. Results of randomised double-blind placebo-controlled studies indicate that tolterodine 4 mg/day (administered as immediate-release tablets 2mg twice daily or extended-release capsules 4mg daily) is superior to placebo in improving micturition diary variables in patients with overactive bladder. Moreover, tolterodine 2mg twice daily is as effective as oxybutynin 5mg 3 times daily. Maximum treatment effects with both drugs occurred after 5 to 8 weeks of treatment and improvements were maintained during long term treatment for up to 24 months. In a pooled analysis of four 12-week studies, equivalent and significant reductions in micturition frequency (-2.3 and -2.0 vs -1.4, p < 0.001) and the incidence of urge incontinence episodes (-1.6 and -1.8 vs -1.1, p < 0.05) were reported for tolterodine 2mg twice daily and oxybutynin 5mg 3 times daily compared with placebo. Functional bladder capacity was also significantly increased. Improvements in patient perceptions of their urgency symptoms and of problems caused by their bladder condition were significantly greater during treat...Continue Reading

References

Jan 1, 1990·European Journal of Clinical Pharmacology·G AlvánU Gundert-Remy
Jul 1, 1988·The Journal of Urology·J G OuslanderC L Yong
Feb 1, 1983·British Journal of Urology·H H MeyhoffJ Nordling
May 30, 1997·European Journal of Pharmacology·L NilvebrantB Sparf
Nov 14, 1997·British Journal of Urology·M JohannessonA Mattiasson
Dec 24, 1997·BMJ : British Medical Journal·C A DonnellanJ R Playfer
Jan 9, 1998·British Journal of Obstetrics and Gynaecology·C J KelleherS Salvatore
Jan 22, 1998·Journal of the American Geriatrics Society·I R KatzK D'Angelo
Oct 17, 1998·Neurourology and Urodynamics·P E Van KerrebroeckJ M Soler
Mar 19, 1999·Experimental Physiology·K E Andersson
Dec 9, 1995·PharmacoEconomics·W R LenderkingM A Testa
Apr 8, 1999·European Journal of Pharmacology·M YonoS Ueda
May 27, 1999·PharmacoEconomics·R M O'ConorG Kobelt-Nguyen
Oct 30, 1999·International Urogynecology Journal and Pelvic Floor Dysfunction·H P DrutzS Radomski
Apr 8, 2000·Drugs & Aging·A M Comer, K L Goa

❮ Previous
Next ❯

Citations

Mar 5, 2003·BJU International·A MattiassonUNKNOWN Tolterodine Scandinavian Study Group
Jul 31, 2004·Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists·C Scully, J-V Bagan
Jun 21, 2005·International Journal of Clinical Practice·V Nitti, S Taneja
Jul 6, 2007·Current Medical Research and Opinion·Susan C BolgeGeorge J Wan
Jul 2, 2009·Clinical Pharmacokinetics·Oxana Doroshyenko, Uwe Fuhr
Aug 9, 2012·Expert Opinion on Drug Metabolism & Toxicology·Umberto Leone Roberti MaggioreSimone Ferrero
Sep 1, 2017·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Rajan RajabalayaSheba R David
Oct 9, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Alan D Garely, Lara Burrows
Feb 14, 2006·Nature Clinical Practice. Urology·Vinay Kalsi, Clare J Fowler
Jul 8, 2015·Current Urology Reports·Mauro GacciSergio Serni
Mar 11, 2008·The Journal of Pharmacology and Experimental Therapeutics·Shuji MaruyamaShizuo Yamada
Sep 28, 2006·International Urogynecology Journal and Pelvic Floor Dysfunction·Ho-Leung Jimmy MakWai Mei Anny Tong
Sep 17, 2003·Oral Diseases·C Scully
Apr 17, 2007·Drugs & Aging·Ragnar Asplund
Jun 10, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Masayo OishiToshio Suwa
Oct 25, 2012·International Neurourology Journal·Shizuo YamadaYoshihiko Ito
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Eric S Rovner
Aug 13, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael G Oefelein
Dec 13, 2007·Journal of Computer-aided Molecular Design·Ann E Cleves, Ajay N Jain
Aug 23, 2012·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Sahar KarimiPatricia W Slattum
Jun 13, 2002·International Journal of Urology : Official Journal of the Japanese Urological Association·Jeong Gu LeeTack Lee
Feb 13, 2003·The Urologic Clinics of North America·Mike B Siroky
Mar 24, 2020·Organic Letters·Hongliang ZhaoSenmiao Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.